Accept Cookies?
Provided by OpenGlobal E-commerce

Please wait while your page loads ...

Minoryx Therapeutics receives FDA Orphan Drug Designation for leriglitazone in Friedreich’s Ataxia

Leriglitazone (MIN-102) is a novel, brain penetrant, orally bioavailable and selective PPARγ agonist
Second Orphan Drug Designation granted by the FDA for leriglitazone in addition to X-linked adrenoleukodystrophy (X-ALD)
Potential for seven years of marketing exclusivity in the USA upon approval in the orphan designation indication



Can't see this document? Click Here

SHARE

FacebookTwitterLinkedInYoutube
ra-philly-18.jpg

 

Archived in
  Scientific News


 

 

Tagged in
FARA Scientific News


Site Map     Privacy Policy      Service Terms      Contact      Charity Navigator